Alkermes(US:ALKS)2024-05-01 14:24Financial Performance - Q1 2024 - Total revenue increased to $350.4 million, a 22% increase compared to $287.6 million in Q1 2023[10] - Proprietary net sales reached $233.5 million, a 9% increase from $214.7 million in Q1 2023[10] - LYBALVI® net sales increased significantly by 50%, reaching $57.0 million compared to $38.0 million in Q1 2023[10] - VIVITROL® net sales saw a slight increase of 1%, reaching $97.7 million compared to $96.7 million in Q1 2023[10] - ARISTADA® net sales decreased by 2%, totaling $78.9 million compared to $80.1 million in Q1 2023[10] - Manufacturing and royalty revenue increased by 60% to $116.8 million, up from $72.9 million in Q1 2023[10] Financial Expectations - 2024 - The company anticipates total revenues between $1.5 billion and $1.6 billion for the year ending December 31, 2024[12] - The company projects GAAP net income between $350 million and $390 million and EBITDA between $445 million and $485 million[12] - Non-GAAP net income is expected to be between $465 million and $505 million[12] Product Sales Outlook - 2024 - VIVITROL® net sales are projected to be between $410 million and $430 million[13] - ARISTADA® net sales are expected to range from $340 million to $360 million[13] - LYBALVI® net sales are projected to be between $275 million and $295 million[13]